TScan Therapeutics
Boston, US · Founded 2018 · 152 employees on LinkedIn · 7 known investors
A company focused on developing clinical treatments aimed at improving patient outcomes.
Founders & leadership
DS
RC
Robert CraneExecutive
Board
LH
SK
CM
Campbell MurrayBoard director
HS
CW
TB
Timothy BarberichBoard director
Investors · 7
Astellas Venture Management LLCSouth San Francisco · $200K – $5M
Bessemer Venture PartnersRedwood City · $5M – $100M
Longwood FundBoston
RA CapitalBoston
6 Dimensions CapitalreportedGrand Caymanvia Hannes Smarason · board
Longwood Special SituationsreportedBoston
PitangoreportedTel Aviv · $4M – $100Mvia Ittai Harel · board
Reported raises · per SEC filings
Form D private placements$123.3M disclosed across 2 rounds · 2019–2021
▶$100MraisedJan 2021 · 16 investors · BiotechnologyRule 506(b)
▶$100MraisedJan 2021 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ittai HarelDirector
- Nandita ShangariDirector
- Christoph WestphalDirector
- Brian SilverDirector
- Doug FambroughDirector
- Timothy BarberichDirector
- David SouthwellExecutive Officer, Director
- Andrew HedinDirector
- Offering amount
- $100M
- Amount sold
- $100M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$23.3MraisedJul 2019 · 9 investors · BiotechnologyRule 506(b)
▶$23.3MraisedJul 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lea HachigianDirector
- David SouthwellExecutive Officer, Director
- Steve KrausDirector
- Campbell MurrayDirector
- Hannes SmarasonDirector
- Christoph WestphalDirector
- Robert CraneExecutive Officer
- Timothy BarberichDirector
- Offering amount
- $23.3M
- Amount sold
- $23.3M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Robinhood33 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha27 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwits26 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Solu25 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with TScan Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does TScan Therapeutics do?
- A company focused on developing clinical treatments aimed at improving patient outcomes.
- Who are TScan Therapeutics's investors?
- TScan Therapeutics's investors include Astellas Venture Management LLC, Bessemer Venture Partners, Longwood Fund, RA Capital, 6 Dimensions Capital, Longwood Special Situations, Pitango.
- How much funding has TScan Therapeutics raised?
- TScan Therapeutics has disclosed $123.3M raised across 2 rounds.
- Where is TScan Therapeutics headquartered?
- TScan Therapeutics is headquartered in Boston, US.